When researchers engineered a mouse to disable what they thought was the sole starting point for the RBM20 gene, they expected the heart cells to stop making the protein entirely. Instead, the mice kept producing it—just in a shorter form. That surprising finding led Dr. Michael Radke and colleagues at the Max Delbrück Center to uncover a hidden layer of genetic regulation in the human heart that could reshape how scientists approach treating heart failure and cardiomyopathy.
The RBM20 protein acts as a maestro in heart muscle cells, orchestrating a molecular editing process called alternative splicing that allows a single gene to produce multiple versions of proteins. One of its most crucial jobs is controlling titin, a giant protein that functions like a molecular spring, giving the heart its essential flexibility. When RBM20 goes wrong, the heart loses its elasticity, triggering severe cardiomyopathies and heart failure—conditions that can be devastating. Understanding how RBM20 itself is controlled, then, has direct implications for millions of patients worldwide.
Using RNA sequencing, ribosome profiling, and molecular imaging on heart tissue from mice, rats, and human patients, the research team discovered that the RBM20 gene does not rely on a single transcription start site as previously believed, but instead activates from multiple starting points. These different entry points produce distinct isoforms—different versions of the same protein—each with potentially different roles in the heart.
The timing of this discovery adds another layer of insight. The researchers found that the balance between RBM20 isoforms is tightly regulated around birth, a critical moment when the heart transitions from supporting fetal function to adult function. This developmental precision suggests the isoforms serve distinct purposes at different stages of life.
What emerged from studying human heart tissue was even more intriguing: disease-specific patterns tied to isoform balance. In hypertrophic cardiomyopathy—where heart muscle becomes abnormally thick—the total RBM20 increased in disease samples compared to healthy controls, but this rise was driven largely by the shorter isoform. In dilated cardiomyopathy, where the heart enlarges and weakens, both isoforms increased, with a more pronounced rise in the longer version. These differences suggest that each disease may involve a distinct molecular miscalculation.
"It is not only the amount of RBM20 that matters, but also which version of the protein is produced," explains Dr. Michael Gotthardt, senior author and Group Leader of the Translational Cardiology and Functional Genomics lab at the Max Delbrück Center. This insight opens a new therapeutic frontier. Since altering RBM20 activity can make heart muscle more flexible, targeting not just how much protein is made but which isoform is produced could allow researchers to fine-tune heart muscle stiffness with greater precision and fewer side effects.
The findings, published in Nature Communications, reveal that the heart's regulatory systems operate with far greater sophistication than previously understood. As researchers move forward, they plan to deepen their understanding of how each RBM20 isoform functions and test their findings in larger patient cohorts and disease models—work that could eventually translate into more targeted treatments for millions living with heart disease.